Compare MRKR & GIFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRKR | GIFT |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 22.0M |
| IPO Year | 2010 | 2019 |
| Metric | MRKR | GIFT |
|---|---|---|
| Price | $0.95 | $0.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.87 | N/A |
| AVG Volume (30 Days) | 60.0K | ★ 69.9K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.61 | ★ 52.05 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $83,181,716.00 |
| Revenue This Year | $19.61 | $6.02 |
| Revenue Next Year | $375.85 | $8.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.84 | $0.44 |
| 52 Week High | $2.46 | $1.29 |
| Indicator | MRKR | GIFT |
|---|---|---|
| Relative Strength Index (RSI) | 31.50 | 40.12 |
| Support Level | N/A | $0.44 |
| Resistance Level | $1.31 | $1.07 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 5.58 | 43.13 |
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Giftify Inc operates in the incentive and rewards industry with a focus on retail, dining, and entertainment experiences, as the owner and operator of digital platforms, CardCash.com, Restaurant.com, and Takeout7.com. CardCash.com is a secondary gift card exchange platform, allowing consumers and retailers to buy and sell gift cards at various scales from several retailers; Restaurant.com is a restaurant-focused digital deals brand, connecting digital consumers and businesses by offering dining, retail, and entertainment deal options at several restaurants and retailers; and Takeout7 is a restaurant technology company offering online ordering solutions and AI-powered digital marketing services. Giftify has one segment, the sale of gift cards and discount certificates to its customers.